
    
      To determine the objective response rates of cisplatin and gemcitabine with or without
      SUBATM-itraconazole in patients with chemotherapy-na√Øve metastatic squamous non-small cell
      lung cancer.

      To assess the changes in tumor blood flow as measured by contrast enhanced MRI scanning in
      patients with metastatic squamous non-small cell lung cancer treated with cisplatin and
      gemcitabine with or without SUBATM-itraconazole.
    
  